Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTURANE vs PROBENECID AND COLCHICINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.
Treatment of chronic gout,Prophylaxis of acute gouty attacks during initiation of allopurinol or uricosuric therapy,Off-label: Prevention of calcium oxalate calculi in hyperuricosuric patients
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
200-400 mg orally twice daily
One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.
Terminal elimination half-life is approximately 4–6 hours for the parent drug; active sulfide metabolite has a half-life of 12–16 hours. Clinically, twice-daily dosing maintains therapeutic levels.
Probenecid: Terminal half-life 6-12 hours (dose-dependent; prolonged at higher doses due to saturable tubular secretion). Colchicine: Terminal half-life 20-40 hours (range 9-30 hours in healthy subjects; prolonged in renal impairment up to 50-60 hours).
Primarily hepatic oxidation and glucuronidation; minor CYP450 involvement.
Probenecid: hepatic via glucuronidation and oxidation; colchicine: hepatic via CYP3A4 and P-glycoprotein.
Renal excretion: approximately 50% of the dose as unchanged drug and its active sulfide metabolite via glomerular filtration and tubular secretion; biliary/fecal: ~30%, primarily as metabolites.
Probenecid: Renal excretion of unchanged drug and metabolites; approx. 75-95% of dose eliminated in urine, with <5% as unchanged probenecid. Colchicine: Primarily fecal excretion (about 65%) via biliary excretion; renal excretion accounts for about 20-30% of elimination, with enterohepatic recirculation.
99% bound, primarily to albumin.
Probenecid: 85-95% bound to albumin. Colchicine: 30-50% bound to albumin.
0.15–0.3 L/kg, indicating limited extravascular distribution; primarily remains in plasma and extracellular fluid.
Probenecid: 0.15 L/kg (indicates distribution primarily in extracellular fluid). Colchicine: 2-8 L/kg (large Vd indicating extensive tissue distribution, particularly into leukocytes and other cells).
Oral: Approximately 90% absorbed, but extensive first-pass metabolism reduces systemic bioavailability of parent drug to 30–40%; active sulfide metabolite contributes to efficacy.
Probenecid: Oral bioavailability nearly complete (approx. 100%) with extensive metabolism. Colchicine: Oral bioavailability 25-50% (first-pass metabolism and P-glycoprotein efflux in gut); bioavailability listed for oral route.
Contraindicated if Cr Cl <30 m L/min. For Cr Cl 30-50 m L/min, reduce dose by 50%. For Cr Cl >50 m L/min, no adjustment.
GFR 30-50 m L/min: reduce dose to one tablet daily. GFR 10-29 m L/min: one tablet every 2-3 days. GFR <10 m L/min or dialysis: contraindicated.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce colchicine dose by 50%. Child-Pugh C: contraindicated.
Not recommended for use in pediatric patients due to lack of safety and efficacy data.
Not recommended for pediatric use. For acute gout in adolescents, consider alternative therapy.
Start at low end of dosing range (200 mg twice daily); monitor renal function. Caution due to increased sensitivity and renal impairment.
Start at lowest dose (one tablet daily), monitor renal function and for toxicity due to age-related decreased renal function.
None.
None.
Acute gouty attacks may occur during initiation; prophylactic colchicine or NSAIDs recommended,Monitor renal function; dose adjustment in renal impairment,Avoid in patients with high urinary uric acid output to prevent uric acid stones,May potentiate warfarin; monitor INR,Cross-allergenicity with sulfonamides possible
Hematologic toxicity (bone marrow suppression), neuromuscular toxicity (especially with renal impairment), severe diarrhea, drug interactions (CYP3A4 and P-gp inhibitors), use caution in elderly and renal/hepatic impairment.
Severe renal impairment (Cr Cl <50 m L/min),History of hypersensitivity to sulfinpyrazone or sulfonamides,Active peptic ulcer disease,Blood dyscrasias,Uric acid nephropathy or stone formation
Hypersensitivity to probenecid or colchicine, severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, concurrent use of P-gp or CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) in patients with renal/hepatic impairment, blood dyscrasias, uric acid kidney stones.
Avoid alcohol as it increases uric acid levels and may decrease drug efficacy. Maintain adequate hydration; avoid excessive intake of high-purine foods (e.g., organ meats, sardines, anchovies) to help control gout.
Limit consumption of high-purine foods (e.g., organ meats, anchovies, sardines, red meat, shellfish) as they can exacerbate gout. Avoid alcohol, particularly beer and liquor, which increase uric acid production and reduce probenecid efficacy. No specific food interaction with colchicine; maintain adequate hydration.
Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 10 times the human dose. However, due to its potential to inhibit platelet aggregation, use during pregnancy, especially near term, may increase the risk of maternal and fetal hemorrhage. First trimester: No specific fetal risks identified, but caution advised. Second trimester: Risks unclear; avoid unless necessary. Third trimester: Potential for premature closure of ductus arteriosus (unlikely as it is not an NSAID) and bleeding risk; avoid near term.
First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformations. Probenecid is not teratogenic in animal studies. Second and third trimesters: No evidence of fetal harm from either drug, but insufficient data. Avoid during pregnancy unless benefit outweighs risk.
Sulfinpyrazone is excreted into human milk in small amounts. The milk-to-plasma (M/P) ratio is not well established but is likely low (<0.2). Due to potential adverse effects in the nursing infant (e.g., bleeding risk, interference with platelet function), caution is recommended. The benefits of breastfeeding should be weighed against the potential risks, and alternative therapies considered.
Colchicine is excreted into human milk in low concentrations; M/P ratio not established. Probenecid is excreted in milk in amounts likely negligible (M/P ratio ~0.5). Both considered compatible with breastfeeding, but monitor infant for diarrhea (colchicine).
Pregnancy can alter pharmacokinetics of drugs due to increased plasma volume, renal blood flow, and hepatic metabolism. For sulfinpyrazone, no specific dose adjustment guidelines are established for pregnancy. Given its uricosuric action, the increased glomerular filtration rate during pregnancy may enhance clearance, potentially requiring higher doses to maintain therapeutic effect. However, due to potential risks, use should be avoided if possible. If used, monitor serum uric acid levels and adjust dose accordingly, starting with the lowest effective dose.
No specific pharmacokinetic data in pregnancy; however, increased renal clearance and volume of distribution in pregnancy may reduce probenecid and colchicine plasma concentrations. Consider dose adjustment based on clinical response and toxicity monitoring, but no standard recommendations exist.
Anturane (sulfinpyrazone) is a uricosuric agent used for chronic gout. It is contraindicated in patients with peptic ulcer disease due to GI irritation. Monitor renal function and uric acid levels. Avoid use in patients with a history of uric acid stones; maintain high fluid intake to prevent stone formation. Not effective in acute gout attacks. Discontinue at least 48 hours before surgery to avoid bleeding risk due to antiplatelet effects.
Colchicine levels can increase with concurrent use of P-glycoprotein inhibitors (e.g., amiodarone, verapamil, clarithromycin) or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Probenecid can raise plasma concentrations of penicillins, cephalosporins, and indomethacin. Monitor for colchicine toxicity (nausea, diarrhea, myopathy) especially in renal impairment; reduce dose in chronic kidney disease. Probenecid may inhibit renal excretion of drugs and can cause uricosuria, so ensure high fluid intake to prevent urate stones.
Take with food or milk to reduce stomach upset.,Drink at least 8 glasses of water daily to prevent kidney stones.,Avoid aspirin and other salicylates as they reduce drug effectiveness.,Report any signs of bleeding (bruising, black stools) or stomach pain.,Do not stop suddenly without consulting your doctor.,This drug is not for acute gout attacks; continue other medications as prescribed.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of water (at least 8 glasses per day) while taking probenecid.,Colchicine can cause severe diarrhea or vomiting; stop and call your doctor if this occurs.,Avoid alcohol, which can worsen gout and interfere with probenecid's effect.,Do not start new medications (especially antibiotics, antifungal, or heart medications) without consulting your doctor due to drug interactions.,Report unexplained muscle pain, weakness, numbness, or tingling immediately (colchicine myopathy).,Keep this and all medications out of reach of children.
No interactions on record
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTURANE vs PROBENECID AND COLCHICINE, answered by our medical review team.
ANTURANE is a Uricosuric that works by Uricosuric agent; inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. PROBENECID AND COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTURANE and PROBENECID AND COLCHICINE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTURANE is: 200-400 mg orally twice daily. The standard adult dose of PROBENECID AND COLCHICINE is: One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTURANE and PROBENECID AND COLCHICINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTURANE is classified as Category C. Anturane (sulfinpyrazone) is a uricosuric agent. There are no adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at dos. PROBENECID AND COLCHICINE is classified as Category A/B. First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.